Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
NEO-CORT-DOME is a fixed-dose combination otic suspension containing glacial acetic acid, hydrocortisone, and neomycin sulfate, approved in 1966 for treatment of ear infections and inflammatory conditions of the external auditory canal. The formulation combines antibiotic activity (neomycin) with anti-inflammatory (hydrocortisone) and antimicrobial/pH-modifying (glacial acetic acid) properties to address bacterial otitis externa.
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), brand teams are typically focused on narrow defensive strategies and cost management rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
NEO-CORT-DOME offers limited career growth opportunities given its LOE-approaching status and zero linked job count, making it a defensive rather than growth-oriented assignment. Roles on this product are typically focused on portfolio maintenance, compliance, and managed decline rather than brand-building or clinical innovation.
Worked on NEO-CORT-DOME at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.